Please try another search
Memphis Pharmaceuticals & Chemical Industries reported earnings results for the nine months ended March 31, 2024. For the nine months, the company reported sales was EGP 664.58 million compared to EGP 440.47 million a year ago. Net income was EGP 166.37 million compared to EGP 35.06 million a year ago.
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Revenue | 234.79 | 247.14 | 182.65 | 223.37 |
Gross Profit | 76.34 | 100.4 | 53.12 | 74.76 |
Operating Income | 70.36 | 64.1 | 26.04 | 59.34 |
Net Income | 83.48 | 58.12 | 24.76 | 55.38 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Total Assets | 1127.34 | 1004.16 | 795.79 | 785.66 |
Total Liabilities | 1059.62 | 856.04 | 667.63 | 680.7 |
Total Equity | 67.73 | 148.12 | 128.16 | 104.95 |
Period Ending: | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -92.61 | 96.49 | 137.26 | 361.5 |
Cash From Investing Activities | 5.58 | 8.86 | 3.31 | 0.249 |
Cash From Financing Activities | 64.91 | 133.06 | -294.29 | |
Net Change in Cash | -22.12 | 238.41 | 140.57 | 67.46 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review